

Title (en)  
PHARMACEUTICAL FORMULATIONS CONTAINING 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN

Title (de)  
PHARMAZEUTISCHE FORMULIERUNGEN MIT 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN

Title (fr)  
PREPARATIONS PHARMACEUTIQUES CONTENANT 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCINE

Publication  
**EP 1853238 A4 20080723 (EN)**

Application  
**EP 06736517 A 20060228**

Priority  
• US 2006007210 W 20060228  
• US 65669505 P 20050228

Abstract (en)  
[origin: WO2006094029A2] A pharmaceutical formulation comprising 17-AAG in an amount from about 1 mg/mL to about 5 mg/mL dissolved in a vehicle comprising (i) a first component that is an aprotic, polar solvent in an amount between about 0.1 and about 10 volume %; and, (ii) a second component that is an aqueous mixture comprising between about 5.0 and about 55.0 volume % long chain triglycerides, in an amount between about 90.0 and 99.9 volume %.

IPC 8 full level  
**A61K 31/04** (2006.01); **A61K 9/107** (2006.01); **A61K 31/33** (2006.01); **A61K 47/18** (2006.01); **A61K 47/20** (2006.01); **A61K 47/24** (2006.01); **A61K 47/44** (2006.01)

CPC (source: EP US)  
**A61K 9/0019** (2013.01 - EP); **A61K 31/04** (2013.01 - EP); **A61K 31/33** (2013.01 - EP); **A61K 31/395** (2013.01 - EP US); **A61P 1/02** (2017.12 - EP); **A61P 1/04** (2017.12 - EP); **A61P 1/14** (2017.12 - EP); **A61P 1/16** (2017.12 - EP); **A61P 1/18** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 5/48** (2017.12 - EP); **A61P 7/06** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 9/14** (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 11/02** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 17/02** (2017.12 - EP); **A61P 17/04** (2017.12 - EP); **A61P 17/06** (2017.12 - EP); **A61P 21/00** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 35/02** (2017.12 - EP); **A61P 35/04** (2017.12 - EP); **A61P 37/00** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **A61P 37/08** (2017.12 - EP); **A61P 41/00** (2017.12 - EP)

Citation (search report)  
• [DY] US 6682758 B1 20040127 - TABIBI S ESMAIL [US], et al  
• [Y] WO 2004082676 A1 20040930 - CONFORMA THERAPEUTICS CORP [US], et al  
• [Y] KLANG S ET AL: "Design and evaluation of submicron emulsions", 1 January 1998, DRUG TARGETING AND DELIVERY, HARWOOD ACADEMIC PUBLISHERS, CHUR, CH, PAGE(S) 119 - 152, ISSN: 1058-241X, XP008092691  
• [Y] GOETZ M P ET AL: "Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer", JOURNAL OF CLINICAL ONCOLOGY 20050220 US, vol. 23, no. 6, 20 February 2005 (2005-02-20), pages 1078 - 1087, XP002483323, ISSN: 0732-183X  
• [Y] BANERJI UDAI ET AL: "Preclinical and clinical activity of the molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin (17AAG) in malignant melanoma.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 44, July 2003 (2003-07-01), & 94TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; WASHINGTON, DC, USA; JULY 11-14, 2003, pages 587, XP008092562, ISSN: 0197-016X  
• See references of WO 2006094029A2

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)  
**WO 2006094029 A2 20060908; WO 2006094029 A3 20070412**; CA 2596867 A1 20060908; EP 1853238 A2 20071114; EP 1853238 A4 20080723; JP 2008531708 A 20080814

DOCDB simple family (application)  
**US 2006007210 W 20060228**; CA 2596867 A 20060228; EP 06736517 A 20060228; JP 2007558167 A 20060228